Ravi Vij & Dr. Nitin Jain Discuss AMPLIFY: Acalabrutinib + Venetoclax + Obinutuzumab in CLL
Автор: MyCancerHaven for Healthcare Professionals
Загружено: 2025-06-30
Просмотров: 27
Ravi Vij Discussing with Dr. Nitin Jain, MD on AMPLIFY: First-Line Fixed-Duration Acalabrutinib + Venetoclax + Obinutuzumab Vs CIT in CLL
In this expert discussion, Dr. Ravi Vij speaks with Dr. Nitin Jain, MD, about the AMPLIFY clinical trial, evaluating first-line fixed-duration therapy using Acalabrutinib + Venetoclax + Obinutuzumab (AVO) versus traditional chemoimmunotherapy (CIT) in Chronic Lymphocytic Leukemia (CLL).
🔬 Topics covered:
Overview of AMPLIFY trial design
Key differences between AVO and CIT regimens
Clinical significance and future treatment implications
Expert perspectives on tolerability, efficacy, and patient outcomes
This video is valuable for hematologists, oncologists, researchers, and CLL care teams.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
